Cargando...

Immunotherapy: Who is Eligible?

Recurrent and/or metastatic head and neck cancer portends a poor prognosis with traditional treatments, but current immunotherapy with immune checkpoint inhibitors has the potential to improve these clinical outcomes. This review focuses on the major breakthroughs that have led to our current unders...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Otolaryngol Clin North Am
Autores principales: Wang, Daniel, Gilbert, Jill, Kim, Young J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282181/
https://ncbi.nlm.nih.gov/pubmed/28755708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.otc.2017.04.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!